查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601198

血漿蛋白治療市場：依產品、應用分類 - 2025-2030 年全球預測

Plasma Protein Therapeutics Market by Product (Albumins, C1-esterase Inhibitors, Coagulation Factors), Application (Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

血漿蛋白治療市場2023年估值為325.5億美元，預計到2024年將達到361.9億美元，複合年成長率為11.37%，預計到2030年將達到691.8億美元。

血漿蛋白療法包括源自人類血漿蛋白的治療方法，用於治療血友病、免疫力缺乏和罕見疾病等疾病。其中包括旨在滿足關鍵患者需求的治療藥物，例如免疫球蛋白、白蛋白和凝血因子。需求在於這些蛋白質提供的獨特治療益處，通常使它們對於沒有其他選擇的患者至關重要。其應用範圍廣泛，從凝血病和免疫力缺乏的治療和管理到急診醫學的重症加護。最終用途主要是醫院、專科診所和研究機構，這些地方迫切需要有效的治療方法。該市場是由罕見疾病的增加、血漿分餾技術的進步以及醫療保健支出的增加等因素所推動的。免疫球蛋白需求的快速成長和重組療法的技術進步，以及新興地區因醫療基礎設施改善而帶來的市場擴張，推動了最新的商機。為了利用這些機會，公司應專注於策略夥伴關係和區域擴張。然而，市場成長目前受到治療成本上漲、嚴格的法律規範以及血漿捐贈道德問題等限制因素的挑戰。此外，產品製造的複雜性和有限的血漿供應也構成了主要障礙。最佳創新領域包括開發新的血漿治療方法、提高血漿採集效率以及探索基因工程以改善基因工程替代品。該市場的主要特徵是競爭激烈，策略合併、收購和聯盟在推動成長方面很常見。公司應優先投資新型療法和潛在合成替代品的研究，以擴大供應。總體而言，由於技術創新和准入範圍擴大，市場可望成長，但必須克服成本、監管和供應鏈複雜性的挑戰。

主要市場統計
基準年[2023] 325.5億美元
預測年份 [2024] 361.9億美元
預測年份 [2030] 691.8億美元
複合年成長率（%） 11.37%

市場動態：快速發展的血漿蛋白治療市場的關鍵市場洞察

血漿蛋白治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 自體免疫疾病和神經系統疾病的盛行率增加
    • 患者一生需要定期輸液或注射
    • 血漿蛋白治療的患者可近性和可負擔性迅速增加
  • 市場限制因素
    • 血漿蛋白療法的副作用
  • 市場機會
    • 血漿蛋白相關研究開發活動的活性化
    • 開發高效血漿蛋白萃取/製造程序
  • 市場挑戰
    • 關於血漿蛋白處理的嚴格規定

波特五力：駕馭血漿蛋白治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解血漿蛋白治療市場的外部影響

外部宏觀環境因素在塑造血漿蛋白治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解血漿蛋白治療市場的競爭格局

血漿蛋白治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣血漿蛋白治療市場供應商的績效評估

FPNV定位矩陣是評估血漿蛋白治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 自體免疫疾病和神經系統疾病的盛行率增加
      • 患者一生需要定期輸液和注射
      • 迅速提高患者血漿蛋白治療的可近性和可負擔性
    • 抑制因素
      • 血漿蛋白治療的不良反應
    • 機會
      • 血漿蛋白相關的研發活動增加
      • 開發高效的蛋白質血漿萃取和製造程序
    • 任務
      • 關於血漿蛋白處理的嚴格規定
  • 市場區隔分析
    • 產品：增加使用 C1 酯酶抑制劑來控制和預防與 HAE 相關的腫脹發作
    • 應用：擴大血漿蛋白療法在癌症和自體免疫疾病擴散導致的繼發性免疫力缺乏中的應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章血漿蛋白治療市場：依產品

  • 白蛋白
  • C1酯酶抑制劑
  • 凝血因子
  • 超免疫球蛋白
  • 免疫球蛋白

第7章血漿蛋白治療市場：依應用分類

  • 遺傳性血管性水腫
  • 特發性血小板減少紫斑症
  • 原發性免疫力缺乏
  • 繼發性免疫力缺乏缺陷

第8章美洲血漿蛋白治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太血漿蛋白治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲/中東/非洲血漿蛋白治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • GC Biopharma 在印尼舉行血漿分餾工廠奠基儀式
    • Plasmagen Biosciences 在班加羅爾 Kolar 開設了最先進的新血漿產品製造工廠
    • 武田將耗資 7.7 億美元在日本興建血漿分餾治療工廠

公司名單

  • Bio Products Laboratory Ltd.
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • DiaPharma
  • GC Biopharma corp
  • AmerisourceBergen Corporation
  • Laboratory Corporation of America Holdings
  • Bruker Corporation
  • Octapharma AG
  • KalVista Pharmaceuticals
  • Emergent BioSolutions
  • FFF Enterprises, Inc.
  • Plasma Technologies, LLC
  • LFB SA
  • Kamada Ltd.
  • PlasmaGen BioSciences Pvt. Ltd.
  • Reliance Industries Limited
  • Thermo Fisher Scientific, Inc.
  • Grifols, SA
  • China Biologic Products Holdings, Inc.
  • Hemarus Therapeutics Limited
  • Access Biologicals LLC
  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Kedrion SpA
Product Code: MRR-030EE4851670

The Plasma Protein Therapeutics Market was valued at USD 32.55 billion in 2023, expected to reach USD 36.19 billion in 2024, and is projected to grow at a CAGR of 11.37%, to USD 69.18 billion by 2030.

Plasma Protein Therapeutics involves treatments derived from human plasma proteins for diseases such as hemophilia, immune deficiencies, and rare disorders. The scope encompasses therapies like immunoglobulins, albumin, and clotting factors designed for critical patient needs. The necessity lies in the unique therapeutic benefits these proteins offer, often essential for patients who lack alternatives. Applications extend from treatment and management of clotting disorders and immune system deficiencies to critical care in emergency medicine. End-use is primarily in hospitals, specialized clinics, and research institutions, where there is a dire need for effective therapies. The market is driven by factors like increasing prevalence of rare diseases, technological advancements in plasma fractionation, and rising healthcare expenditure. Latest opportunities arise from the surge in demand for immunoglobulins and innovations in recombinant therapies, coupled with market expansion in emerging regions due to improving healthcare infrastructure. To capitalize on these opportunities, businesses should focus on strategic partnerships, and regional expansions. However, market growth is currently challenged by constraints such as the high cost of therapies, stringent regulatory frameworks, and the ethical issues surrounding plasma donation. Additionally, complexities in product manufacturing and limited plasma supply pose significant hurdles. The best areas for innovation include developing new plasma-derived therapies, enhancing plasma collection efficiency, and exploring genetic engineering to improve recombinant alternatives. The market is primarily characterized by intense competition, where strategic mergers, acquisitions, and collaborations are common in fostering growth. Businesses should prioritize investment in research for novel therapies and potential synthetic alternatives to boost supply. Overall, the market is poised for growth, driven by innovations and expanding access, but must navigate the challenges of cost, regulation, and supply chain complexities.

KEY MARKET STATISTICS
Base Year [2023] USD 32.55 billion
Estimated Year [2024] USD 36.19 billion
Forecast Year [2030] USD 69.18 billion
CAGR (%) 11.37%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Plasma Protein Therapeutics Market

The Plasma Protein Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased Prevalence of Autoimmune and Neurological Diseases
    • Need for Regular Infusions or Injections Throughout the Life of the Patient
    • Surging Access and Affordability of Plasma Protein Therapies for Patients
  • Market Restraints
    • Adverse Effects of Plasma Protein Therapeutics
  • Market Opportunities
    • Increasing Research and Development Activity Related to the Plasma Protein
    • Development of Efficient Protein Plasma Extraction/Manufacturing Process
  • Market Challenges
    • Strict Regulations Pertaining to Handling of Plasma Protein

Porter's Five Forces: A Strategic Tool for Navigating the Plasma Protein Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Plasma Protein Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Plasma Protein Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Plasma Protein Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Plasma Protein Therapeutics Market

A detailed market share analysis in the Plasma Protein Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Plasma Protein Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Plasma Protein Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Bio Products Laboratory Ltd., CSL Limited, Takeda Pharmaceutical Company Limited, DiaPharma, GC Biopharma corp, AmerisourceBergen Corporation, Laboratory Corporation of America Holdings, Bruker Corporation, Octapharma AG, KalVista Pharmaceuticals, Emergent BioSolutions, FFF Enterprises, Inc., Plasma Technologies, LLC, LFB SA, Kamada Ltd., PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Thermo Fisher Scientific, Inc., Grifols, S.A., China Biologic Products Holdings, Inc., Hemarus Therapeutics Limited, Access Biologicals LLC, ADMA Biologics, Inc., Baxter International Inc., and Kedrion S.p.A..

Market Segmentation & Coverage

This research report categorizes the Plasma Protein Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Albumins, C1-esterase Inhibitors, Coagulation Factors, Hyperimmune Globulins, and Immunoglobulins.
  • Based on Application, market is studied across Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Secondary Immunodeficiency.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased Prevalence of Autoimmune and Neurological Diseases
      • 5.1.1.2. Need for Regular Infusions or Injections Throughout the Life of the Patient
      • 5.1.1.3. Surging Access and Affordability of Plasma Protein Therapies for Patients
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse Effects of Plasma Protein Therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Research and Development Activity Related to the Plasma Protein
      • 5.1.3.2. Development of Efficient Protein Plasma Extraction/Manufacturing Process
    • 5.1.4. Challenges
      • 5.1.4.1. Strict Regulations Pertaining to Handling of Plasma Protein
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
    • 5.2.2. Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Plasma Protein Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Albumins
  • 6.3. C1-esterase Inhibitors
  • 6.4. Coagulation Factors
  • 6.5. Hyperimmune Globulins
  • 6.6. Immunoglobulins

7. Plasma Protein Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Hereditary Angioedema
  • 7.3. Idiopathic Thrombocytopenic Purpura
  • 7.4. Primary Immunodeficiency Disorder
  • 7.5. Secondary Immunodeficiency

8. Americas Plasma Protein Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Plasma Protein Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Plasma Protein Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
    • 11.3.2. PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru
    • 11.3.3. Takeda to build USD 770 million plasma-derived therapy plant in Japan

Companies Mentioned

  • 1. Bio Products Laboratory Ltd.
  • 2. CSL Limited
  • 3. Takeda Pharmaceutical Company Limited
  • 4. DiaPharma
  • 5. GC Biopharma corp
  • 6. AmerisourceBergen Corporation
  • 7. Laboratory Corporation of America Holdings
  • 8. Bruker Corporation
  • 9. Octapharma AG
  • 10. KalVista Pharmaceuticals
  • 11. Emergent BioSolutions
  • 12. FFF Enterprises, Inc.
  • 13. Plasma Technologies, LLC
  • 14. LFB SA
  • 15. Kamada Ltd.
  • 16. PlasmaGen BioSciences Pvt. Ltd.
  • 17. Reliance Industries Limited
  • 18. Thermo Fisher Scientific, Inc.
  • 19. Grifols, S.A.
  • 20. China Biologic Products Holdings, Inc.
  • 21. Hemarus Therapeutics Limited
  • 22. Access Biologicals LLC
  • 23. ADMA Biologics, Inc.
  • 24. Baxter International Inc.
  • 25. Kedrion S.p.A.

LIST OF FIGURES

  • FIGURE 1. PLASMA PROTEIN THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PLASMA PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PLASMA PROTEIN THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023